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BASIC SCIENCE
P-glycoprotein mediated antiepileptic drug transport; a role in refractory epilepsy?
Graeme Sills, P. Kwan, E. CM de Lange, E. Butler & M. Brodie
Epilepsy Unit, University Department of Medicine & Therapeutics, Western Infirmary, Glasgow G11
6NT, UK
Recent evidence suggests that the drug-transport molecule P-glycoprotein (P-gp) encoded by the multi-drug resistance (mdr)
gene, may play a causative role in refractory epilepsy. We have conducted a pharmacokinetic investigation of eight antiepileptic
drugs (AEDs) in genetically modified mdr1a(−/−) knock-out mice device of P-gp at the blood-brain barrier.
72 mdr1a(−/−) mice were randomised to receive either phenobarbital (20 mg kg−1), phenytoin (20 mg kg−1), carba-
mazepine (20 mg kg−1), sodium valproate (200 mg kg−1), vigabatrin (500 mg kg−1), lamotrigine (5 mg kg−1), gabapentin
(50 mg kg−1) or topiramate (50 mg kg−1) by subcutaneous injection. At 30, 60 and 240 minutes post-dosing, three animals
from each group were sacrificed, a truncal blood sample obtained and their brains removed. Thereafter, samples were analysed
for plasma and brain concentrations of appropriate AED. A parallel group of 72 wild-type (genetically normal) mice served as
controls.
Brain/plasma concentration ratios for carbamazepine (30 min), lamotrigine (240 min), gabapentin (30 min) and topiramate
(30, 60 & 240 min) were significantly (P < 0.05) higher in mdr1a(−/−) knockout mice than in wild-type controls. There were
no significant differences in brain/plasma ratios for any other AEDs under investigation.
These results suggest that several currently used AEDs are substrates for P-gp transport and support the potential contributory
role of mdr gene expression in drug-resistant epilepsy.
Immune mechanisms of epilepsy: anti-CNS antibodies in adult onset rasmussen’s encephalitis
A. Scott, R. Mathias & I. Hart
Neuroimmunology Research Group, Department of Human Anatomy and Cell Biology, New Medical
School, Ashton Street, Liverpool L69 3GE, UK
Rasmussen’s encephalitis (RE) causes severe epilepsy and progressive neurological deficits. It is a focal, confluently spreading,
cortical inflammation initially described in children. Anti-inotropic-glutamate receptor subunit (iGluR3) antibodies have been
implicated in the pathogenesis of the childhood variant RE, however, the role of autoimmunity in adult-onset RE is less clear.
In this study we performed extensive serum and CSF auto-antibody screens on six adult-onset RE patients in order to char-
acterize autoimmune abnormalities in adult variant RE.
Sera from 4/6 RE patients bound to multiple protein bands on SDS-PAGE in particular, two proteins with mw of 60 and
120Da. Sera from 2/6 RE patients showed specific hippocampal, neuronal reactivity on imunohistochemistry. On ELISA, two
patients had serum anti-glutamic acid decarboxylase (GAD) antibodies.
These results suggest that the prominent bands are unlikely to be iGluR3 suggesting these may be novel autoantibodies. We
conclude that anti-CNS autoantibodies are common with a complex, heterogeneous response that may help trigger or maintain
adult-onset RE, possibly in a manner different to childhood variant RE.
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NON-EPILEPTIC SEIZURES
An innovative treatment for non-epileptic seizures: clinical outcome at six month follow-up
Sara Mitchell-O’Malley, A. Deale, L. Goldstein, B. Toone & J. Mellers
c/o Room 32, Outpatient Department, Department of Neuropsychiatry, The Maudsley Hospital, London
SE5 8A3, UK
Background: Despite a growing literature on Non-Epileptic Seizures (NES), little is known about the treatment of this disorder.
We report on the first study of treatment using a Cognitive Behavioural approach and the results at six month follow-up.
Purpose: To evaluate the effectiveness of cognitive behavioural therapy as a treatment for adults who experience NES.
Method: Twenty adults (17 female/3 male) with NES were offered 12 sessions of cognitive behavioural therapy on a weekly
basis. Clinical measures were administered at weeks 1, 6 and 12 and then at follow-up intervals of 1, 3, 6 and 12 months to
measure treatment outcome, seizure reduction and global functioning.
Results: Sixteen people completed treatment. Results at six month follow-up demonstrate a significant reduction in seizure
frequency in fourteen participants (P = 0.001), improvement in global functioning was apparent in all sixteen participants
(P = 0.005) and nine people have returned to full-time employment. We will also report follow-up data which will include a
comparison of health service contacts at pre-treatment and 12 month follow-up.
Use of out-patient video-eeg recording in the diagnosis of non-epileptic seizures
Aileen McGonigal, M. Oto, A. Russell, R. Gillham, J. Greene & R. Duncan
c/o Department of Neurology, Institute of Neurological Sciences, Southern General Hospital,
1345 Govan Road, Glasgow G51 4TF, UK
Video-EEG recording of typical events is helpful in diagnosing psychogenic non-epileptic seizures (NES). Resources for pro-
longed inpatient videotelemetry recording are however limited. Various methods of inducing NES have been used for diagnostic
purposes, some raising ethical concerns. We report a randomised controlled trial of simple suggestion techniques with out patient
video EEG in recording habitual NES.
Twenty-nine patients (23 female, six male; age range 17–68), with suspected NES, were randomised to out-patient video-
EEG with active suggestion (n = 15) or standard video-EEG (n = 14). Those in the suggestion group had a doctor present
during the test (AMcG), and were told that hyperventilation or photic stimulation (as part of a standard out-patient EEG) might
bring on an attack. Events recorded were confirmed as typical of the patient’s attacks by an eye-witness.
In the active suggestion group, 10/15 (66%) had habitual attacks. In the control group, 4/14 (29%) had habitual attacks. All
were electroclinically NES. One patient who had a habitual NES but had abnormal interictal EEG, and the 14/29 (48%) patients
who did not have a typical attack, will have inpatient video EEG.
Short out-patient video-EEG recording of NES is practicable and may improve current use of diagnostic resources. Some
patients have attacks without suggestion, but even simple (and honest) suggestion significantly improves diagnostic yield.
High expressed emotion in carers of adults with epileptic or non-epileptic seizures
Laura Goldstein, N. Stanhope, E. Kuipers, S. Mitchell-O’Malley, F. Cronin, B. Toone & J. Mellers
Department of Psychology, Institute of Psychiatry, DeCrespigny Park, London SE5 8AF, UK
High Expressed Emotion (EE) (a high level of criticism, hostility or emotional overinvolvement or some combination or these)
towards a patient by their carer (spending ≥10 hours a week with the person) was detected, using a 5-minute speech sam-
ple, in 19/36 (53.3%) carers of adults with epileptic seizures (ES) and in 11/15 (73%) carers of adults with non-epileptic
seizures (NES). The groups of high-EE carers did not differ in the mean weekly time spent caregiving, although mean number
of years spent caregiving was significantly higher for the high-EE epilepsy carers. Whilst these two groups of carers showed
equivalent knowledge about medical and social aspects of epilepsy, the NES-patients’ carers believed that their relatives’ ill-
ness would last for a shorter time than did the relatives of the ES patients. The carers did not differ on measures of anxiety,
depression, self-esteem, perceived strain, coping styles or health-related locus of control beliefs. Their respective patient groups
differed only in terms of self-esteem (the NES patients had lower self-esteem than the ES patients) and the proportion who had
suffered seizure-related injuries in the past year (NES > ES). Further investigations of potential interactions between patients’
and carers’ characteristics are therefore needed to explain the apparently higher prevalence of high EE in the carers of people
with NES as opposed to ES.
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Non-epileptic seizures following general anaesthetics
Ida Lichter, B. Toone & J. Mellers
Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK
Although post-operative seizures are rare, cases of seizure-like disorders, sometimes lasting up to several weeks, have been
described particularly in association with propofol anaesthesia. Clinical features included opisthotonus and other dystonias.
Five patients who developed seizures following a general anaesthetic are described. All patients attended the Neuropsychiatry
Epilepsy Unit at the Maudsley Hospital and King’s College Hospital. Three patients had a history of anxiety, depression and
sexual abuse. In all cases, repeated seizures followed the initial attack and descriptions of clinical features were characteristic
of dissociative attacks. In addition, neurological examination was normal and ictal EEG’s captured during video-telemetry or
photic stimulation showed well-preserved alpha rhythm and no epileptiform changes. Although in retrospect, it is not possible to
determine whether the initial attacks were epileptic, subsequently these patients had a firm diagnosis of pseudoseizures. In two
cases where interictal EEGs showed some abnormality, it is possible that both epileptic and pseudoepileptic seizures co-existed.
We suggest that anaesthetic agents may trigger pseudoseizures by inducing a state of altered awareness, particularly in
vulnerable personalities, and that a psychogenic basis for seizures occurring after general anaesthesia needs to be considered.
INVESTIGATION
Relationship between histopathological diagnosis of hippocampal sclerosis & pre-surgical
measurement of hippocampal volume and T2 relaxation time in patients with intractable
temporal lobe epilepsy
Christine Denby, U. Weishmann, D. Smith, M. Rossl, D. Chadwick & N. Roberts
Magnetic Resonance & Image Analysis Research Centre, University of Liverpool, Pembroke Place,
Liverpool L69 3BX, UK
Introduction: It is well established that hippocampal sclerosis (HS) is characterised by selective neuronal cell loss and reactive
gliosis, suggesting it is unlikely that one will occur without the other in the majority of Temporal Lobe Epilepsy (TLE) patients.
The aim of this study was to examine the extent to which increased hippocampal T2 relaxation time and reduced hippocampal
volume were both present on MRI in TLE patients with a histopathological diagnosis of HS.
Method: A FSE imaging sequence was acquired along the long axis of the hippocampus using a 1.5 SIGNA whole body MR
imaging system.
Results: Thirty-six out of 68 post-surgical patients had a histopathological diagnosis of medial temporal sclerosis (MTS). In
this group, 14 inconsistencies were noted, volume asymmetry (atrophy) was lateralising in 35 (97%) cases, in 22 (61%) patients,
T2 relaxation agreed with the volumetry. However, T2 relaxation time alone failed to lateralise MTS. In one case, volumetry
and T2 relaxation time both failed to identify MTS.
Discussion: T2 relaxation time is a valuable indicator of hippocampal sclerosis. However, patients with histological HS and an
ipsilateral decrease in hippocampal volume do not always have an increase in T2 relaxation time. Observed differences in T2
could be due to bilateral sclerosis, non-specific increases in water content, myelin abnormalities, unidentified dual pathology
and varying degrees of hippocampal sclerosis.
Voxel based morphometry of hippocampal and extra hippocampal effects of unilateral temporal
lobe epilepsy
Simon Keller, C. Mackay, T. Barrick, C. Denby & N. Roberts
The Magnetic Resonance and Image Analysis Research Centre (MARIARC), University of Liverpool,
Pembroke Place, Liverpool L69 3BX, UK
Introduction: Voxel Based Morphometry (VBM) in combination with MRI was used to investigate the extent of hippocampal
abnormalities and extra-hippocampal involvement in temporal lobe epilepsy patients with evidence of left and right Medial
Temporal Sclerosis (MTS).
Methods: Stereological techniques were used to estimate hippocampal volume on MR images in a group of 231 TLE patients.
Groups of 40 left MTS, 36 right MTS and a control group of 35 were analysed using VBM techniques in SPM 99 software.
Results: Hippocampal sclerosis was characterised by anterior left hippocampal reduction in left MTS and posterior right hip-
pocampal reduction in right MTS. Extra-hippocampal abnormalities in right MTS included excess in the right parahippocampal
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gyrus, cingulate gyrus, and temporo-parietal convexity and bilateral cerebellar reduction. Right amygdala excess was associated
with left MTS.
Discussion: VBM analysis has provided results consistent with modern design stereology regarding the extent of hippocampal
atrophy in patients with unilateral MTS. Both hippocampal and extra-hippocampal abnormalities were found to be different in
left and right MTS. Work is in progress to investigate whether VBM could provide a basis for screening for the presence of
unilateral MTS in individual patients.
Foramen ovale recordings in the context of quantitative magnetic resonance imaging
Udo Wieshmann, C. Denby, P. Eldridge, N. Roberts, B. Tedman, D. Chadwick & D. Smith
The Walton Centre for Neurology and Neurosurgery, Lower Lane, Fazakerley, Liverpool L9 7LJ, UK
Purpose: To evaluate the role of Foramen Ovale Recordings (FOR) in non-lesional temporal lobe epilepsy in the context of
quantitative Magnetic Resonance Imaging (qMRI).
Methods: Patients had surface EEG (sEEG), Wada test and qMRI (measurements of hippocampal volume and T2 relaxation
time). FOR were performed if sEEG was not lateralising or qMRI was normal. We compared the outcome of three groups:
I. Patients with FOR and normal qMRI (n = 16), II. Patients with FOR and hippocampal abnormalities on qMRI (n = 41),
III. Patients without FOR and hippocampal abnormalities on qMRI (n = 29).
Results: In group I, 15 of 16 patients were rejected because FOR failed to identify the seizure onset zone, 1 patient failed
surgery. In group II, 12 of 41 patients became seizure free after surgery, 13 failed surgery, 16 were rejected in group III, 16 of
29 patients became seizure free, 5 failed surgery and 8 were rejected. The 3 groups were significantly different with respect to
outcome (P < 0.001).
Conclusion: FOR are of limited, if any, value in patients with no abnormality on qMRI. FOR may have a role in patients with
hippocampal abnormalities on qMRI but non-lateralising surface EEG.
SIDE-EFFECTS
Measuring visual field defects in children exposed to vigabatrin
Emma Spencer, A. Kouros, W. Whitehouse, R. Robinson, D. Calver, R. Harrison, K. Manuchehri &
G. Harding
Clinical Neurophysiology Unit, Aston University, Aston Triangle, Birmingham B4 7ET, UK
Introduction: Vigabatrin is an antiepileptic drug that acts by irreversibly binding to GABA-T causing an increase in GABA
available in the brain. Since 1997, an increasing number of studies have been linking vigabatrin to a specific pattern of peripheral
visual field loss in one-third of patients. The majority of studies have not included a paediatric population due to difficulties
assessing visual field function using standard perimetry tests in those children with a developmental age below nine years. This
is a particular problem as vigabatrin is effective against infantile spasms.
Methods: A field-specific visual evoked potential (the H-Stimulus), was developed which consisted of a central stimulus (0–5◦
radius), a blank annulus and a peripheral stimulus (30–60◦ radius). Both the central and peripheral stimuli consist of black
and white checks that increase in size with eccentricity. The checks reverse at different rates allowing for two responses to be
recorded monocularly from O2 and O1 referred to Fz. Thirty-nine children, aged 3–15 years, were included in the study, with
perimetry carried out as a comparison.
Results: Thirty-five children complied with the H-Stimulus but only 11 could perform perimetry. Using the summed amplitude
of the peripheral response from O2 and O1, any responses below 10 µv were deemed abnormal. The H-Stimulus identified 3/4
abnormal perimetry results and 6/7 normal perimetry results, giving a sensitivity of 75% and a specificity of 85.7%.
Conclusions: The H-Stimulus is a useful alternative method to perimetry that is both well tolerated by young children and gives
a reliable indication of possible peripheral visual fields loss.
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Prospective study of the development of infants born to mothers with epilepsy
Fiona James, M. Jackson, S. Fairgrieve, S. Lynch & D. Walshaw
Department of Neurology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle Upon Tyne NE1
4LP, UK
Objective: To establish if infants born to mothers with epilepsy are at increased risk of developmental delay and if anti-epileptic
drugs contribute to that delay.
Methods: Our recent prospective study of pregnant women with epilepsy identified 300 women who completed a questionnaire
about their epilepsy, drug treatment and education.
292 women consented to developmental assessment of their children prior to delivery. These infants are being visited by a
paediatrician (blinded to the maternal history) and assessed using Bayley’s scales of development. Assessments are made in the
third year. Development of these children is then compared to that of the general population.
Results: 111 infants have been examined to date: 78 born to mothers on monotherapy (carbamazepine 38, valproate 40), 23/111
(21%) infants have delayed development (P = 0.0215), 8 having severe delay (7.2%, population prevalence 1.5% P = 0.0006).
Developmental delay is associated not only with carbamazepine monotherapy (P = 0.02) and valproate (P = 0.005) in
pregnancy but also with lower maternal educational achievement; only 30% of mothers of delayed children obtained 5 GCSE
passes (A–G) compared to 85% general population (P = 0.0118).
Conclusion: Children born to mothers with epilepsy are at greater risk of delay but the cause is likely to be multifactorial
including maternal education and socioeconomic factors.
Possible beneficial effect of lamotrigine on function and structure of the ovary in women with
epilepsy who have the polycystic ovary syndrome
Helen Yarrow, T. Betts & L. Greenhill
Birmingham University Seizure Clinic, Queen Elizabeth Psychiatric Hospital, Birmingham B15 2QZ, UK
Women with epilepsy, particularly if they acquire it in childhood or adolescence, are more likely to have both polycystic
(polyfollicular) ovaries and the polycystic ovary syndrome than their non-epileptic peer group. This may be due to a direct
epilepsy effect on brain hormone releasing mechanisms. We have some evidence to suggest that women with ‘epilepsy induced’
polycystic ovaries may be more likely to develop the polycystic ovary syndrome if on valproate monotherapy (Betts and Yarrow,
2000), the hormonal parameters of the syndrome may return to normal if the valproate is withdrawn.
During preconceptual substitution of valproate for lamotrigine we have recently observed, in four women, that hormonal
parameters return to normal almost immediately on the exhibition of lamotrigine before the withdrawal of the valproate. Marked
resolution of the size and number of cysts in the ovaries has also been observed after a year. This latter observation might be, of
course, just be a valproate withdrawal effect.
This intriguing observation has been reinforced by a study of a patient who already had hormonal and scanning evidence
of a long-standing polycystic ovary syndrome with very irregular menstruation before developing epilepsy and commencing
lamotrigine. Shortly after starting lamotrigine she began to menstruate regularly, hormonal parameters returned to normal and
re-scanning of her ovaries after a year of being on lamotrigine showed that the size of her ovaries had reduced, as had the size
and number of cysts.
If this intriguing finding is reproduced in a larger sample we will need to speculate about the mechanisms involved. Is it a
direct effect of lamotrigine on the ovary, or on midbrain hormone releasing mechanisms, or something like a metformin effect?
Effect of three drugs (valproate, lamotrigine and carbamazepine) on ovarian structure and
function when used in exclusive monotherapy in women with primary generalised epilepsy
Tim Betts, H. Yarrow & L. Greenhill
Birmingham University Seizure Clinic, Queen Elizabeth Psychiatric Hospital, Birmingham B15 2QZ, UK
We have been studying ovarian structure and function in young women presenting to our clinic with primary generalised
epilepsy, mostly for preconception counselling. We have examined the results in three groups of women who have only ever
taken valproate, carbamazepine or lamotrigine.
The prevalence of polycystic (polyfollicular) ovaries is high in this group of women, almost certainly higher than one would
expect in a normal population of women. There is no difference in the prevalence of polycystic (polyfollicular) ovaries in the
three patient groups suggesting that this increased prevalence is an epilepsy effect rather than a specific drug effect.
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There was, however, a highly significant difference in the prevalence of the polycystic ovary syndrome in the three groups only
women taking valproate in monotherapy, possessing polyfollicular ovaries, had the hormonal characteristics of the syndrome
(there is also clear evidence that the hormonal changes of the syndrome regress if the valproate is withdrawn).
Our interim conclusions are that polycystic ovaries are commoner in women with epilepsy than one would expect by chance
but presumably due to putative effects of epilepsy on midbrain hormone releasing mechanisms; such women may be vulner-
able to some metabolic effect of valproate itself which is reversible. This would suggest that women with epilepsy who have
polycystic (polyfollicular) ovaries should avoid the use of valproate if possible.
The legacy of vigabatrin in a regional epilepsy clinic
A. Nicolson, D. Chadwick & D. Smith
The University Department of Neurosciences, Clinical Sciences Building for Research and Education,
Fazakerley, Liverpool L9 7LJ, UK
Background: Vigabatrin (VGB), the first designer antiepileptic drug, was licensed in 1989. Since 1997 it has become clear
that VGB is associated with a significant risk of asymptomatic irreversible retinopathy. Guidelines restricting its use have been
disseminated, but are these enough?
Methods: This is a retrospective review of 550 patients prescribed VGB between 1989 and 1998. Data is collected on dose/
duration of treatment, results of perimetry, as well as reason for and outcome of discontinuation.
Results: 42 (11%) of the first 400 patients analysed have been lost to follow up whilst still taking VGB. Another 36 (9%)
continue on VGB and remain under review. Visual fields have been tested in 31 (40%) of these patients who may still be on
VGB and were abnormal with no alternative cause in 13 (42%). Seizure control improved in 75 (23%) of those withdrawn from
VGB while only 13 (4%) deteriorated, and 215 (67%) were unchanged.
Conclusions: Preliminary analysis reveals that 20% of those treated with VGB remain on treatment despite the potential serious
visual adverse effects. While visual defects are common in those tested, 54% are not being monitored or counselled. There are
significant cost implications in adherence to guidelines of those staying on treatment and in tracing/assessing those lost to
follow-up. Given that switch over rarely results in deterioration, there is a good case for cessation of VGB in most, if not all,
individuals.
NURSING
A way to help nurses effectively monitor side effects of AED’s
Marie Hooper & Heather Sullivan
Learning Disabilities Directorate, East Resource Centre, Unit 10 Bodmin Business Centre, Harleigh
Road, Bodmin, Cornwall PL31 1AQ, UK
Rationale: Once a Consultant prescribes an AED it is expected that the nurse will be monitoring side-effects. Doctors are
regularly provided with B.N.F.’s, but nurses are expected to monitor without up-to-date information. Will providing nurses with
AED monitoring checklists increase the detection of harmful side-effects?
Method: Twenty RNLD presently monitoring AED’s were surveyed using a simple questionnaire on known common side-
effects of medication and possible clinical signs.
Results:
• Two nurses thought Largactil was an AED.
• One nurse said if people didn’t become ill, they had no side-effects.
• 3/4 of nurses were unaware of any link with AED’s on the menstrual cycle or interaction with the pill.
• Only two nurses were aware that AED’s are available in Brand and proprietary formulations.
Conclusion: Introducing a nurses AED checklist would enable early detection of side-effects and enhance the service provided.
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A pilot study of a nurse led epilepsy clinic using telemedicine
Ena Bingham, V. Patterson & R. Chua
Room 115, Bostock House, Royal Hospital Trust, Belfast BT12 6BA, UK
The recent Clinical Standards Advisory Group report has criticised the conventional care given to epilepsy patients. It found
that there was strong support for Epilepsy Specialist Nurses whose numbers have been increasing since 1988, and mentioned
Telemedicine as a possible way of improving the service to patients.
In Northern Ireland we have shown that Telemedicine, using interactive video consultation, is a safe and effective way to deal
with both acute neurological admissions and new neurological outpatients.
Epilepsy centres, as envisaged in the CSAG report may not be practical in widely scattered rural communities, and so we
decided to use a nurse-led approach with graduated Telemedicine support from a Consultant Neurologist in two rural hospitals.
We present the findings of a pilot study.
To date 16 patients have been studied in a graduated way, first by the nurse alone, second, if necessary, with a telephone call
to the Neurologist and third, if necessary with video conferencing to the Neurologist.
40% of the patients were managed by the nurse alone, with only 20% requiring video link to Neurologist.
Patient satisfaction in all groups was high with all agreeing to be seen that way in future.
This graduated approach deserves further study as a way of optimising epilepsy care in rural areas.
‘What a difference a nurse makes’
Jan Maxwell & Irene Hamill
Epilepsy Unit, Western Infirmary, Glasgow G11 6NL, UK & West of Scotland Regional Epilepsy Service,
Southern General Hospital, Glasgow G51 4TF, UK
It is estimated that more than 30 000 people in Scotland have epilepsy. There are few true epilepsy specialists for these people to
see. Many people with epilepsy will never see a specialist but will have their condition managed by their General Practitioner.
With this in mind the Practice Nurse has been identified as potentially being a key resource in optimising the care of those
with epilepsy. Recognising that nurses receive very little information about epilepsy during their training, the first annual Short
Course in Epilepsy for Practice Nurses in Scotland was held in 1998. The course was organised and run by two epilepsy
specialist nurses in Glasgow.
There have been 3 four-day courses run with a total of 71 nurses attending. Epilepsy knowledge before and after was assessed
using the Epilepsy Knowledge Questionnaire. A follow-up survey shows marked improvement in epilepsy awareness audit in
primary care and patient review. Results show the magnitude of the potential improvement in services, discussion covers course
content and nurse’s epilepsy knowledge. It is concluded that the value of this course to people with epilepsy is immensely
important and that epilepsy specialist nurses have a major role in providing education.
A nurse led triage clinic for new onset seizures: clinically successful but economically
disastrous
Lyn Greenhill, L. Pritchett, K. Smith & T. Betts
Birmingham University Seizure Clinic, Queen Elizabeth Psychiatric Hospital, Birmingham B15 2QZ, UK
We have run for some years a fast track clinic in our service for people with new onset seizures diagnosed as epilepsy by their
general practitioners, based on our one-stop clinic (where the patient has an EEG, MRI scan, full history and examination the
first time they come, with the second visit two or three weeks later to assess the results and to develop a treatment plan). Audit
of such a clinic has shown that only 21% of presenting patients actually have epilepsy which means that many patients may be
receiving unnecessary investigation. To supplement our service we therefore set up a nurse-led Triage clinic in which patients
were seen very rapidly after referral for an assessment as to whether or not they needed full investigation. Only 15% of the
62 patients assessed had epilepsy for certain: in 22% the diagnosis was uncertain (and remained so on consultant review). The
commonest non epilepsy diagnosis was syncope (30%). There was complete nurse/consultant diagnostic agreement. 41% had a
subsequent EEG and 30% a subsequent MRI.
This seemed to us therefore an effective use of our stretched resources until our accountants pointed out that acting more
efficiently was actually costing us money. The inflexible nature of NHS funding means that for every one-stop patient seen and
assessed we receive a fixed sum, some five times the amount of a single assessment in the Triage clinic. However, if ‘Triage’
patients then need further investigation this is not funded and the cost has to be met from our own resources. Nine months of a
Triage clinic has already cost us over £20 000 and since the unit is critically dependent on external funding this has meant that
we have had to abandon this new clinic. This lead us to ruefully conclude that our National Health Service, which successive




Can properly trained companion dogs reduce human seizure frequency as well as predict
seizure onset?
Stephen Brown & V. Strong
Plymouth Postgraduate Medical School Developmental Disabilities Research & Education Group, Unit
10 Bodmin Business Centre, Bodmin PL31 1AH, UK
There are anecdotal reports of dogs spontaneously alerting to and/or anticipating human seizures. We have described elsewhere
that this may have a serious adverse effect on both human and canine health.
We have also shown that it is possible to train selected dogs alongside humans with seizures so that the dog can give a
useful warning of a seizure to the person without harming dog or human. Important points include introducing the selected
dog to the human and socialising them together under supervision, and then training the dog to recognise and anticipate that
person’s seizures using a reward-based operant conditioning paradigm. Intermittent positive reinforcement is used to maintain
the learning effect. Follow-up with the dog trainer is an important part of the approach.
An unexpected finding was that the human subjects reported a reduction in seizure rate. We assessed this in more detail in a
ten subject pilot study. After three months baseline data collection, a three month training period was carried out, and follow-
up data was collected for a further six months. There was a significant reduction in seizure frequency between baseline and
follow-up (P = 0.002).
Following this pilot study, further more detailed work is being carried out.
Calcium antagonists as an add-on therapy for drug-resistant epilepsy: a systematic review
Rungsan Chaisewikul, N. Baillie & T. Marson
University Department of Neurological Science, Clinical Science Centre for Research & Education,
Lower Lane, Liverpool L9 7LJ, UK
Purpose: To systematically review evidence for effects of an add-on calcium antagonist for drug-resistant epilepsy.
Methods: Randomized placebo controlled trials recruiting patients with drug-resistant epilepsy were included. Search strategy
included searching Cochrane Library (issue 1, 2001) and Specialist trial register of the Cochrane Epilepsy Group. Outcomes
were (a) 50% or greater reduction in seizure frequency, (b) treatment withdrawal, (c) side-effects.
Results: Eight trials of flunarizine (363 patients), one trail of nifedipine (22 patients) and two trials of nimodipine (39 patients)
were included. Flunarizine showed a weak antiepileptic effect with a substantial withdrawal rate and various potential side-
effects, namely altered concentration, blurred vision, diplopia, dizziness, fatigue, irritability, vomiting, and insomnia. Nifedip-
ine and nimodipine did not demonstrate efficacy in seizure reduction although were without a significant rate of treatment
withdrawal or side-effects.
Conclusions: The calcium antagonists reviewed are associated with significant side-effects and only flunarazine demonstrated
an effect on seizures which was modest. There is, therefore, insufficient evidence to support the use of calcium antagonists as
an add-on therapy for drug-resistant epilepsy.
Epilepsy and antimalarial medication
C. Andrews, A. Richens & J. Mumford
Epilepsy Research Foundation, P.O. Box 3004, London W4 1XT, UK
The risk of contracting malaria is high when travelling to some parts of the world, and prophylactic medicines are normally
recommended to protect the traveller. These measures are especially important in people who have epilepsy because problems
can occur when combining antimalarial and antiepileptic tablets.
Chloroquine (contained in Avloclor and Nivaquin) is one of the most widely used antimalarial preventative treatments, and
mefloquine (Larium) is generally recommended when travelling to countries where the malarial parasite is resistant to chloro-
quine. The British National Formulary (BNF) advises people with epilepsy or a past history of epilepsy not to take these
medications because they can cause seizures.
Two antimalarial drugs are available without prescription in the UK, proguanil (Paludrine) and chloroquine, and the Epilepsy
Research Foundation was concerned that chloroquine might be made available to people with epilepsy despite being contra-
indicated. Results from a survey undertaken in 16 pharmacies found that they were incorrectly sold over the counter in 17% of
cases.
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Following discussions with Dr Behrens (from The Hospital for Tropical Diseases in London) who writes the Antimalarials
Section for the BNF, revisions have been made to the Epilepsy sub-section in the latest issue, and are detailed in the poster.
Antiepileptic drug compliance in pregnancy: assessment by hair analysis
Phil Smith, J. Williams, V. Myson, G. Jones, S. Steward, M. Kerr & J. Wilson
The Welsh Epilepsy Unit, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK
Concerns over teratogenicity of antiepileptic drugs (AED) must be balanced against the risks to the foetus of maternal seizures.
AED compliance assessment by history or a single blood level cannot reliably reflect overall drug taking behaviour. We have
assessed AED compliance in pregnant epilepsy patients compared to non-pregnant controls, using hair analysis to indicate drug
taking behaviour.
15–20 hairs were cut from the posterior vertex scalp of 21 pregnant women (mean age 25.2 years) and 31 non-pregnant
epilepsy outpatients (mean age 32.0 years; 13 female). Eight other pregnant women were excluded as, on valproate monother-
apy, no hair assay is currently available. AED concentration (carbamazepine, lamotrigine) was measured in 1 cm hair segments
by high performance liquid chromatography (HPLC). The coefficient of variation (%CV) of AED concentration between hair
segments by subject was used to assess drug compliance.
Three of the 21 pregnant patients showed no AED in the proximal hair segments, the concentration having fallen rapidly
in the first trimester; one later disclosed having stopped her prescribed AED. The remaining 20 showed compliance similar to
non-pregnant controls (mean %CV 13.65 and 17.21 respectively [NS]).
In conclusion, these pregnant women mostly showed AED compliance similar to non-pregnant controls. A significant pro-
portion (14%), however, had covertly discontinued AED after conception.
Phenytoin versus valproate monotherapy: a meta-analysis
A. Marson, C. Tudur & P. Williamson
Department of Neurological Science, Clinical Sciences Centre, Lower Lane, Fazakerley, Liverpool L9
7LJ, UK
Rationale: To overview the evidence from randomized controlled trials comparing phenytoin and valproate monotherapy.
Methods: We report a meta-analysis using individual patient data. Our search included the Cochrane Library, Medline, hand-
searching relevant journals and contacting pharmaceutical companies. Outcomes were time to: (i) withdrawal of treatment,
(ii) 12-month remission, (iii) first seizure. Results are expressed as hazard ratios (HR) with 95% confidence intervals. A HR >
1 indicated that an event is more likely on phenytoin.
Results: Data were available for 669 patients from five trials, representing 60% of the patients from the 11 trials that met our
inclusion criteria. The main overall results (HR 95% Cl) were: (i) time to treatment withdrawal 0.96 (0.70–1.32), (ii) time to
12 month remission 1.04 (0.78–1.38), (iii) time to first seizure 0.92 (0.74–1.14). These results suggest no overall difference
between drugs. A test for an interaction between drug and seizure type (generalized versus localization related) was also non-
significant.
Conclusions: We have found no evidence of an overall difference between phenytoin and valproate monotherapy and no evi-
dence to support the belief of an interaction between drug and seizure type. If future trials are to inform practice, they need to
be designed and powered accordingly.
Further audit of the practicalities of switching from valproate to lamotrigine in women with
primary generalised epilepsy before conception
Tim Betts, Lyn Greenhill & H. Yarrow
Birmingham University Seizure Clinic, Queen Elizabeth Psychiatric Hospital, Birmingham B15 2QZ, UK
As previously reported (Betts and Fox, 1999) (Betts, Morgan and Fox, 2000), we currently attempt to switch women with
epilepsy contemplating pregnancy from valproate to lamotrigine monotherapy.
A pilot audit of this practice suggests the following (46 patients).
(a) 56% of patients transferred from valproate monotherapy to lamotrigine monotherapy successfully but the process takes a
long time and cannot be hurried. It was significantly more likely to be successful if the switch was carried out by a nurse
specialist, and/or a consultant/nurse team, if blood levels monitoring and EEG monitoring were used; junior doctors and
GPs were much less likely to carry the switch to completeness.
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(b) We had used a linear model for decreasing the valproate dose and increasing the lamotrigine dose (decreases in valproate
dosing and increases the lamotrigine dosing ran pari passu because valproate inhibits the metabolism of lamotrigine so
that lamotrigine levels will paradoxically fall as valproate doses fall).
(c) Evidence from our own audit (and recent evidence from Sweden) suggests this may not be the most appropriate model.
Most of the decrease in lamotrigine levels consequent upon withdrawal of valproate appears to occur towards the end of
withdrawal and not in a linear fashion, resulting in some unexpected necessary increases in the lamotrigine dose after
valproate has been completely withdrawn. Seizure control was often only maintained if the dose of lamotrigine was three
times higher than at the start of valproate withdrawal.
Possible clinical effectiveness of levetiracetam on resistant photosensitivity—an early
observational study
Tim Betts∗, C. Burrow†, H. Yarrow∗ & L. Greenhill∗
∗Birmingham University Seizure Clinic, Queen Elizabeth Psychiatric Hospital, Birmingham B15 2QZ,
UK and †Vision Sciences Department, University of Aston, Birmingham B4 7ET, UK
Seizures evoked by photo or pattern sensitivity are a not uncommon problem, particularly in the adolescent. They are usually
managed using either valproate or lamotrigine or, in resistant cases, a mixture of both drugs. Some patients, however, continue
to exhibit clinically important photo or pattern sensitivity despite conventional drug treatment. The introduction of levetiracetam
(Keppra) on to the market has enabled us to try it in a few patients with resistant photo or pattern sensitivity. The rationale for
this was our previous observation that levetiracetam may be effective in some forms of resistant primary generalised epilepsy,
particularly juvenile Myoclonic Epilepsy (with which photosensitivity is often associated). A previous single dose study also
suggested that it might be effective in this condition.
Our early experience of its use in patients with resistant photo or pattern sensitivity suggests that it may be highly effective in
this condition, used in conventional doses. Since, at the moment, the drug is not licensed for generalised epilepsies our use of it
in this condition is outwith the license. We suggest formal trials of levetiracetam against photo and pattern sensitivity as soon
as possible.
Use of lamotrigine in monotherapy in women who are pregnant: is dose escalation needed
during the pregnancy?
Tim Betts, Lyn Greenhill & H. Yarrow
Birmingham University Seizure Clinic, Queen Elizabeth Psychiatric Hospital, Birmingham B15 2QZ, UK
The literature suggests that women with epilepsy should escalate the dose of their anticonvulsant during pregnancy particularly
during the third trimester (Betts and Crawford, 1998). Pregnancy causes changes in protein binding of drugs, in liver metabolism,
a increased plasma volume, cardiac output and body water. Lamotrigine is being increasingly used in monotherapy in women
with epilepsy preconceptually (Betts and Fox, 1999) and therefore an increasing number of women taking lamotrigine will go
through pregnancy. We have audited our recent experience of such women.
This audit suggests that to keep the patient seizure free or having no more seizures than usual, the dose of lamotrigine needs
to be increased during pregnancy sometimes by more than twofold: this dose escalation may need to be started sooner in the
pregnancy than previous experience would suggest. Since, like many AEDs, lamotrigine has a neurotoxic threshold, once the
baby is born, the dose of lamotrigine may need to be reduced rapidly very shortly after the birth, if neurotoxic symptoms (ataxia,
nausea, diplopia) are to be avoided: this is not always necessary.
In patients who were seizure free, blood level monitoring of lamotrigine was used to try to preserve seizure freedom: our
impression is that blood level monitoring may not be of much help, but a formal study will be needed to test this properly
starting very early in pregnancy and with a baseline blood level.
Further evidence to suggest that levetiracetam is effective in the management of resistant
juvenile myoclonic epilepsy
Kate Smith, T. Betts & L. Greenhill
Birmingham University Seizure Clinic, Queen Elizabeth Psychiatric Hospital, Birmingham B15 2QZ, UK
We have shown before in a small number of patients with resistant Juvenile Myoclonic Epilepsy (Smith and Betts, 2000) that the
newly introduced anticonvulsant levetiracetam (Keppra) may be effective in the management of patients with resistant Juvenile
Myoclonic Epilepsy.
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The introduction of levetiracetam onto the UK market has enabled us to test its efficacy in this condition further. We report our
total experience of this drug both in open trials and as prescribed medication in 24 patients with this condition. 15/24 patients
became totally seizure-free (in particular losing their morning jerks which are sometimes difficult to control with conventional
medication). 7 had at least a 50% reduction in seizures: only 2 failed to respond.
Although marketed levetiracetam is not currently licensed for patients with primary generalised epilepsy we will continue to
use it because of our audited experience. Formal trials of levetiracetam in this condition are long overdue.
Audit of early clinical experience of the new anticonvulsant levetiracetam (Keppra)
Tim Betts, Kate Smith, Lorna Pritchett, Vanya Ellens, Lyn Greenhill & Mary Eaton
Birmingham University Seizure Clinic, Queen Elizabeth Psychiatric Hospital, Birmingham, B15 2QZ, UK
In clinical trials levetiracetam has been shown to be an effective anticonvulsant with a low side effect profile. Clinical trials,
however, are carried out in patients with resistant epilepsy and who are carefully selected for exclusion criteria. They do not
represent the normal run of patients to be encountered in an epilepsy clinic.
Since its introduction onto the UK market in November, because of its promising profile, we have been using it extensively
in our clinic and have been auditing the results. Our early experience, in the first 45 patients to be given the drug, and who
have been taking it for long enough for full evaluation, confirms the impression from clinical trials that it is highly effective,
rendering 51% of these patients seizure free. Of particular interest is that 67% of patients with primary generalised epilepsy
became seizure free (only 37.5% of those with partial onset epilepsy did so). It has an acceptable side effect profile with only
three patients withdrawing because of side effects (nausea and ataxia). It is clearly a broad-spectrum drug. We would urge
formal clinical trials of its use in primary generalised epilepsy as soon as possible.
Our early experience is promising, but it will take more time to determine whether the initial good effects can be maintained,
or whether tolerance will develop.
Vagus nerve stimulation: a case report of temporal lobe epilepsy, unipolar depression and
learning disability
Ekkehart Staufenberg, J. Cochius, M. Graydon, J. McEwen & R. Beach
Medical School, University of East Anglia, UK
Left Vagus Nerve Stimulation (VNS) was licensed by the Food and Drug Administration (FDA) in July 1997 for refractory
localisation related onset seizures in adults and adolescents aged over 12 years and is approved in most European Union
countries for patients with mostly localisation related or generalised seizures.
Indications for VNS to date include non-response to existing anti-epileptic (poly) drug therapy. Other possible indications
involve epilepsy syndromes not conducive to epilepsy neurosurgery-based treatments, or patient resistant to neurosurgical in-
terventions. Epilepsy populations with associated organic brain syndromes—such as frequently linked to Mental Retardation
(ICD10 F72) and Learning Disabilities—also form possible indications.
This report briefly reviews the putative mechanisms of actions of VNS, reviews existing efficacy and safety data, and describes
a single case of a right-handed male with localisation related epilepsy syndrome of temporal lobe type, secondary generalisation,
significant impulsive aggressive conduct, unipolar depressive episodes and associated borderline learning disability.
Twelve months following implantation of a neurocybernetic prosthesis (NCP) the patient is euthymic, has no further suicidal
and deliberate self-harm cognitions, has markedly reduced impulsive assaultative conduct, and has improvement in seizure
frequency and seizure semeiology.
Implications for NCP implantation will be discussed, particularly with a view to epilepsy populations with associated and
complex neuro-psychopathologies.
Levetiracetam add-on for drug-resistant localization related (partial) epilepsy: a systematic
review with meta-analysis
Rungsan Chaisewikul, M. Privitera, J. Hutton & T. Marson
University Department of Neurological Science, Clinical Science Centre for Research & Education,
Lower Lane, Liverpool L9 7LJ, UK
Purpose: To systematically review evidence for effects of add-on levetiracetam for drug-resistant partial seizures.
Methods: Randomized placebo controlled trials recruiting patients with drug-resistant partial seizures were included. Search
strategy included contacting UCB Pharma, searching Cochrane Library (Issue 3, 2000), and Specialist trial register of the
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Cochrane Epilepsy Group. Outcomes were (a) 50% or greater reduction in seizures (responders), (b) treatment withdrawal,
(c) side-effects. Data were combined in meta-analysis. Results are presented as odds ratios with 95% (outcomes (a) and (b))
and 99% (outcome (c)) confidence intervals.
Results: Four trials (1023 patients) were included for treatment withdrawal and side-effect outcomes. Three (904 patients) were
included for 50% responders. The overall OR (95% CI) for 50% responders was 3.81 (2.78, 5.22), and for treatment withdrawal
was 1.25 (0.87, 1.80). For side-effects, the followings were significantly associated with levetiracetam: dizziness 2.36 (1.21,
4.61) and infection 1.82 (1.05, 3.14). Accidental injury was significantly associated with placebo 0.55 (0.32, 0.93).
Conclusions: Levetiracetam has add-on efficacy on drug-resistant partial epilepsy, and seems well tolerated. The trials reviewed
were of short duration (16–24 weeks), and results cannot be used to confirm long-term efficacy. Results cannot be extrapolated
to monotherapy or to other seizure types or syndromes.
The effect of lamotrigine on photoparoxymal responses in the EEG
Caroline Burrow∗, T. Betts†, G. Harding∗, F. Fylan∗ & H. Yarrow†
∗Clinical Neurophysiology Unit, Neurosciences Research Institute, Aston University, Birmingham B4
7ET, UK and †Birmingham University Seizure Clinic, Birmingham B15 2QZ, UK
Photosensitive epilepsy (PSE), which predominately affects females, is usually treated with sodium valproate. However, sodium
valproate has been shown to have an adverse side-effect profile, including teratogenicity, and may be associated with the ex-
pression of the polycystic ovary syndrome. It is clear, therefore, that an alternative treatment for PSE would be valuable.
We have investigated the effect of lamotrigine on photoparoxysmal responses (PPRs) elicited by photic or pattern stimulation
in the EEGs of patients with photosensitive epilepsy. Patients were followed up for 12 months whilst they transferred from
sodium valproate to lamotrigine, or commenced lamotrigine monotherapy.
Results show that patients changing from sodium valproate can achieve equal control with lamotrigine, as indicated by the
EEG.
In patients commencing lamotrigine monotherapy PPRs elicited by photic stimulation are more responsive to lamotrigine than
those evoked by pattern stimulation. In a subgroup of patients commencing lamotrigine, abnormal occipital-posterior temporal
activity replaces the PPRs suggesting that lamotrigine may prevent the generalisation of abnormalities evoked by photic and
pattern stimulation. The results suggest that lamotrigine may be an appropriate substitute for sodium valproate in the treatment
of photosensitive epilepsy.
The use of sodium valproate, lamotrigine and topiramate in idiopathic general epilepsy
A. Nicolson, R. Chaisewikul, D. Smith & D. Chadwick
The University Department of Neurosciences, Clinical Sciences Building for Research and Education,
Fazakerley, Liverpool L9 7LJ, UK
Background: Idiopathic generalised epilepsy (IGE) is a genetically determined condition that is often successfully treated with
antiepileptic drugs (AEDs). Sodium valproate (VPS) is traditionally the drug of choice, but the newer AEDs lamotrigine (LTG)
and topiramate (TPM) are also licensed for use in IGE. However, there have been no comparative randomised controlled trials
allowing an evidenced based choice between these drugs.
Methods: This is a retrospective review of patients with IGE, attending regional paediatric and adult epilepsy clinics. The
retention time on treatment and the incidence of seizure freedom will be compared for each AED combination. Family history
of epilepsy, history of febrile convulsions or IDDM, syndrome diagnosis, together with EEG findings will be recorded and
analysed as possible predictive prognostic factors. Multivariate analysis will assess whether the rank order in which a particular
AED is given influences prognosis.
Results: There are approximately 700 patients with IGE included in the study. Preliminary data on 150 patients showed a family
history of epilepsy in a first degree relative in 33%. 67% had generalised spike wave on EEG with a photoconvulsive response
in 22% and focal abnormality in 16%. Cumulative survival curves will compare retention times on each AED combination, and
these together with the incidences of seizure freedom, are a combined measure of efficacy and tolerability.
Conclusion: With the results from this study we will be able to directly compare the efficacy and tolerability of VPS, LTG, and
TPM in the treatment of IGE, and the factors that may independently influence outcome.
